Inspection Record

Terumo BCT (Canada) Inc. — Health Canada Inspection Findings

Health CanadaInspected 2022-09-13 6 findingsLabeling and packagingEquipment and facilityOther quality systemComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Labeling and packaging

The positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate. The confirmatory tests conducted on samples before or after they were received in Canada were inadequate.

2Equipment and facility

The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.

3Other quality system

The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.

5Equipment and facility

The maintenance of evidence was inadequate for manufacturing, packaging, labelling, required testing, storage, and/or distribution, including the respective conditions.

6Complaint and recall handling

The assessment, recording, follow-up, and/or investigation of complaints and/or other information about potentially defective products was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2022-09-13. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Terumo BCT (Canada) Inc. findings history — including this company's other documentsAll Health Canada findings Health Canada documents, 2022 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.